Marketing approvals for generic drugs may soon be delinked from their patent status in India. This comes as a result of long-standing demand from India’s pharmaceutical industry, which depends heavily on the sale of generic drugs.
India to delink marketing authorisation and patent status
Home/Policies & Legislation
|
Posted 07/01/2011
0
Post your comment
The health ministry is planning to remove a question on the patent status of a drug from the form that medicine companies fill in when applying to the Drug Controller General of India (DCGI) for regulatory approval, a ministry official said.
The proposal follows a meeting in Mumbai, India, in November 2010 between Indian drugmakers and Health Minister Ghulam Nabi Azad.
If deleted, the DCGI will issue approvals only on the grounds of drug quality and efficacy.
The issue will be taken up at the next Drug Testing Advisory Board meeting.
Source: Livemint
Guidelines
Advances in EMA plans to streamline biosimilar assessment
FDA issues guidance on AI use in drug and biologicals regulatory decision making
Related content
ANVISA and Danish Medicines Agency renew health regulatory collaboration
Home/Policies & Legislation Posted 06/05/2025
Colombia and Brazil introduce reforms to enhance healthcare regulation
Home/Policies & Legislation Posted 22/04/2025
Second wave of drugs selected for Medicare price negotiation
Home/Policies & Legislation Posted 11/04/2025
NPRA Malaysia trials new timelines for variation applications
Home/Policies & Legislation Posted 05/11/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment